SCHEMBL4135096

SCHEMBL4135096

CNCc1ccc(-c2c(C)nc(-c3ccccc3O)n(CCc3ccccc3)c2=O)s1

nearest known ligand 0.63

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 5/20 0.63
CASR P41180 19/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138653 0.89 NR1I2 (0.78) NR1I2CASR
SCHEMBL4147846 0.88 NR1I2 (0.65) NR1I2CASR
SCHEMBL4135258 0.88 CASR (0.76) NR1I2CASR
SCHEMBL4140384 0.85 CASR (0.62) NR1I2CASR
SCHEMBL3417598 0.82 CASR (0.60) NR1I2CASR
SCHEMBL3418018 0.81 CASR (0.59) NR1I2CASR
SCHEMBL4135191 0.81 CASR (0.66) NR1I2CASR
SCHEMBL4142560 0.81 CASR (0.78) NR1I2CASR
SCHEMBL4151534 0.81 CASR (0.69) NR1I2CASR
SCHEMBL4143854 0.80 CASR (0.65) NR1I2CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US claimed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB NR1I2 3373/4885CASR 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.